Sponsored Links
BRIEF-Peregrine Pharma drops in premarket after discrepancies discovered in bavituximab trial data
NEW YORK, Sept 24 |
NEW YORK, Sept 24 (Reuters) - Peregrine Pharmaceuticals Inc : * Pharma drops 71.2 percent to $1.55 in premarket after discrepancies discovered in bavituximab trial data
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters